Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
ERCC2	2068	OXALIPLATIN	CHEMBL414804		PharmGKB
ERCC2	2068	CARBOPLATIN	CHEMBL1351		CIViC	19470925
ERCC2	2068	IFOSFAMIDE	CHEMBL1024		PharmGKB
ERCC2	2068	PHENYLTHIOUREA	CHEMBL263376		PharmGKB
ERCC2	2068	FLUOROURACIL	CHEMBL185		PharmGKB
ERCC2	2068	PACLITAXEL	CHEMBL428647		CIViC	19470925

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ERCC2	rs1799793	C	Platinum compounds	efficacy	no	No significant relationship between genotype and drug response was detected.	Allele C is not associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	22761669	982046452
ERCC2	rs13181	G	Platinum compounds	efficacy	no	No significant relationship between genotype and drug response was detected.	Allele G is not associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	22761669	982046456
ERCC2	rs13181	TT	cisplatin	efficacy	no	This SNP was presented as XPD Lys751Gln. No association between outcome and genotype was found for this SNP.	Genotype TT is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GG + GT.	18347182	1183700717
ERCC2	rs1799793	CC	cisplatin	efficacy	no	This SNP was presented as XPD Asp312Asn. No association between outcome and genotype was found for this SNP.	Genotype CC is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	18347182	1183700722
ERCC2	rs13181	T	fluorouracil	efficacy	no		Allele T is not associated with response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to allele G.	25232828	1184886917
ERCC2	rs238406	GT + TT	Platinum compounds	efficacy	no	No significant difference in genotype frequencies were seen between responders and non-responders to treatment. Responders defined as having complete or partial response, and non-responders defined as having stable or progressive disease. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes GT + TT is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	24446315	1296599205
ERCC2	rs1799793	CT + TT	Platinum compounds	efficacy	no	No significant difference in genotype frequencies were seen between responders and non-responders to treatment. Responders defined as having complete or partial response, and non-responders defined as having stable or progressive disease.	Genotypes CT + TT is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.	24446315	1296599211
ERCC2	rs3810366	G	fluorouracil	efficacy	no	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele G is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele C.	28796378	1448926448
ERCC2	rs50872	A	fluorouracil	efficacy	no	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.	28796378	1448926454
ERCC2	rs1799793	CC	bevacizumab	efficacy	no	No significant association with response, progression-free survival or overall survival was found for this variant. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype CC is not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes CT + TT.	27995989	1448568311
ERCC2	rs13181	G	fluorouracil	efficacy	no	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele G is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele T.	28796378	1448926423
ERCC2	rs13181	G	Platinum compounds	efficacy	no	Patients were treated with cisplatin or carboplatin in combination with a third-generation drug (gemcitabine, paclitaxel, pemetrexed or vinorelbine). No significant association with overall response rate (ORR), overall survival (OS) or progression-free survival (PFS) was found for this SNP.	Allele G is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	29662106	1449752396
ERCC2	rs1799793	C	Platinum compounds	efficacy	no	Patients were treated with cisplatin or carboplatin in combination with a third-generation drug (gemcitabine, paclitaxel, pemetrexed or vinorelbine). No significant association with overall response rate (ORR), overall survival (OS) or progression-free survival (PFS) was found for this SNP. Please note that alleles have been complemented to the plus chromosomal strand.	Allele C is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.	29662106	1449752404
ERCC2	rs13181	GG	bevacizumab	efficacy	yes	Patients with the GG genotype had increased response in multivariable analysis. However, note that this was only a "nominally" significant association: formally significant was defined as p<0.0026, and nominally significant as p<0.05. No association with progression-free survival or overall survival was found. Please note that alleles have been complemented to the plus chromosomal strand.	Genotype GG is associated with increased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes GT + TT.	27995989	1448568317
ERCC2	rs238406	T	fluorouracil	efficacy	no	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele T is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.	28796378	1448926429
ERCC2	rs1052555	AA + AG	Platinum compounds	efficacy	yes	Those with the AA or AG genotypes had a decreased likelihood of being a responder to therapy, ascompared to those with the GG genotype. Responders defined as having complete or partial response, and non-responders defined as having stable or progressive disease. Please note alleles have been complemented to the plus chromosomal strand.	Genotypes AA + AG is associated with decreased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	24446315	1296599109
ERCC2	rs1052555	A	fluorouracil	efficacy	no	1,002 patients with gastric cancer and complete genotyping data were included; 694 had chemotherapy treatment, and 308 did not. Median follow-up time was 63.43 months, with 465 deaths (46.4%) at the end. Patients were treated with fluoropyridines, platinum-based chemotherapy, or radiotherapy combinations. Please note: the authors do not distinguish between distinct treatment regimens- simply "chemotherapy".	Allele A is not associated with response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.	28796378	1448926435